US 11,052,119 B2
Cell-based composition and use thereof for treatment of diabetes and associated metabolic disorders and for amelioration of insulin resistance in pre-diabetes
Bernard Sze-Piaw Chin, Selangor (MY); Kong Yong Then, Selangor (MY); and Soon Keng Cheong, Selangor (MY)
Assigned to Cytopeutics Sdn. Bhd., Selangor (MY)
Filed by Cytopeutics Sdn. Bhd., Selangor (MY)
Filed on Feb. 25, 2019, as Appl. No. 16/284,177.
Application 16/284,177 is a division of application No. 15/597,725, filed on May 17, 2017, abandoned.
Claims priority of application No. PI 2016701900 (MY), filed on May 25, 2016.
Prior Publication US 2019/0209620 A1, Jul. 11, 2019
Int. Cl. A61K 35/28 (2015.01); C12N 5/0775 (2010.01)
CPC A61K 35/28 (2013.01) [C12N 5/0665 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method for the treatment of diabetes and its associated metabolic disorders and complications and for amelioration of insulin resistance in pre-diabetes in a human subject, said method comprising administering to said human subject a therapeutically effective amount of a cell-based composition consisting essentially of a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml, wherein the therapeutically effective amount is from 0.25 million to 3.0 million cells/kg body weight.